

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**国药集团**  
SINOPHARM

**CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED**  
**中國中藥控股有限公司**

*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 570)**

**CHANGE OF NON-EXECUTIVE DIRECTOR**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. YANG Shanhua (“**Mr. YANG**”) has resigned as the non-executive Director and a member of each of the audit committee and the remuneration and evaluation committee of the Board, with effect from 19 November 2022 due to change of his work arrangement.

Mr. YANG has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. YANG for his valuable contribution to the Company during his tenure of service.

**APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that Mr. MENG Qingxin (“**Mr. MENG**”), has been appointed as a non-executive Director with effect from 19 November 2022.

The biographical details of Mr. MENG are set out below:

Mr. MENG, aged 42. Mr. MENG was graduated from Northwest Minzu University in environmental engineering in 2003. Mr. MENG has a senior engineering qualification. From August 2003 to August 2007, Mr. MENG served as the technical safety specialist in equipment department of the 200 National Factory; from August 2007 to February 2009, he served as a technical safety specialist in

equipment department of Beijing Aerospace Guanhua Electronics Technology Co., Ltd.; from February 2009 to December 2012, he served as a deputy director of equipment department and a deputy director of safety and security department of Beijing Aerospace Guanhua Electronics Technology Co., Ltd.; from December 2012 to October 2013, he served as a deputy director of the Ninth Standardization Research Office of China Aerospace Science and Technology Corporation. Since October 2013, he has successively served as a senior supervisor, a director assistant and a deputy director of the safety, environmental protection and quality management department of China National Pharmaceutical Group Corporation (currently known as China National Pharmaceutical Group Co., Ltd.).

Save as disclosed above, Mr. MENG (i) does not hold any other position within the Group; (ii) has not held directorships in any other listed companies in the past three years; (iii) has not held any other major appointment and professional qualifications; and (iv) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)).

Mr. MENG will enter into an appointment agreement with the Company in relation to his appointment as the non-executive Director for an initial term of three years. He shall hold office only until the next general meeting of the Company and shall then be eligible for re-election. Thereafter, he is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. The Director’s fee of Mr. MENG is determined with reference to his performance and responsibilities, the Group’s profitability and the prevailing market condition. For the year ending 31 December 2022, it is expected that he will not receive any Director’s fee.

As at the date of this announcement, Mr. MENG does not have any other interest in the shares, underlying shares or debentures of the Company and/or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters concerning Mr. MENG that need to be brought to the attention of the shareholders of the Company, nor is there any information relating to Mr. MENG that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express welcome to Mr. MENG for his appointment as the non-executive Director.

By Order of the Board  
**China Traditional Chinese Medicine Holdings Co. Limited**  
**CHEN Yinglong**  
*Chairman*

Hong Kong, 18 November 2022

*As at the date of this announcement, the Board comprises twelve Directors, of which Mr. CHEN Yinglong, Mr. CHENG Xueren and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.*